Glutamate and Neuropsychiatric Disorders 2022
DOI: 10.1007/978-3-030-87480-3_6
|View full text |Cite
|
Sign up to set email alerts
|

Glutamate in Migraine Neurobiology and Treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 284 publications
0
1
0
Order By: Relevance
“…These actions are potentially mediated by the presence of 5-HT 1D and/or 5-HT 1B receptors on the presynaptic terminal, thus affecting presynaptic Ca 2+ influx [373]. On the other hand, anti-GCRP monoclonal antibodies are thought to prevent NMDA-and AMPA-evoked firing potentiation and the nociceptive activation of second-order neurons [374].…”
Section: Glutamate and Gabamentioning
confidence: 99%
“…These actions are potentially mediated by the presence of 5-HT 1D and/or 5-HT 1B receptors on the presynaptic terminal, thus affecting presynaptic Ca 2+ influx [373]. On the other hand, anti-GCRP monoclonal antibodies are thought to prevent NMDA-and AMPA-evoked firing potentiation and the nociceptive activation of second-order neurons [374].…”
Section: Glutamate and Gabamentioning
confidence: 99%
“…Adicionalmente, novos alvos terapêuticos estão sendo investigados, incluindo inibidores de receptores de CGRP, antagonistas de receptores serotoninérgicos e moduladores de canais iônicos específicos. Estas abordagens promissoras têm o potencial de proporcionar tratamentos mais diversificados e personalizados para os pacientes (Andreou, 2022).…”
Section: Novas Terapias E Abordagensunclassified